In particular, TRPV1 antagonists are currently used as therapeutic agents for heartburn and visceral hypersensitivity, but various TRP channels are likely to be proposed as targets for intestinal diseases.63 The gene discussed is TRPV1; the disease is gastroesophageal reflux disease.